Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
about
Burden and management of chronic kidney disease in Japan: systematic review of the literatureEconomic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review.Managing blood pressure control in Asian patients: safety and efficacy of losartan.Angiotensin inhibition and longevity: a question of hydration.
P2860
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
@en
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
@nl
type
label
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
@en
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
@nl
prefLabel
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
@en
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
@nl
P2093
P2860
P1433
P1476
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
@en
P2093
Chua Chin Teong
Dong Cheol Han
George W Carides
Shang-Jyh Hwang
Thomas A Burke
Wong Kok Seng
Yon Jong Choi
P2860
P304
P356
10.1111/J.1440-1797.2005.00472.X
P577
2005-10-01T00:00:00Z